Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region

Our study is one of few providing discounts and actual prices for 15 cancer medicines, revealing large price variations between and within countries. Additionally, reference prices often fail to provide an accurate indication of the actual price and hospitals have often misguided perceptions on their negotiation performance. Transparent, standardized reporting of prices and coordinated collaborations are essential to strengthen the bargaining power of hospitals and foster informed price negotiations.